Quarterly ResultMay 13, 2026, 07:37 AM
Alto Neuroscience Q1 Net Loss $(26.2)M; Raises $114.9M in Private Placement
AI Summary
Alto Neuroscience reported a net loss of $(26.2) million for the three months ended March 31, 2026, an increase from $(15.2) million in the prior year period, primarily due to higher research and development expenses. Despite the increased loss, the company significantly bolstered its liquidity by completing a private placement in March 2026, raising $114.9 million in net proceeds. Additionally, K2 HealthVentures LLC converted $1.0 million of its outstanding loan balance into common stock.
Key Highlights
- Net loss for Q1 2026 was $(26.2) million, up from $(15.2) million in Q1 2025.
- Research and development expenses increased to $20.3 million in Q1 2026 from $10.0 million in Q1 2025.
- Completed a private placement in March 2026, generating $114.9 million in net proceeds.
- Cash and cash equivalents stood at $263.8 million as of March 31, 2026.
- K2 HealthVentures LLC converted $1.0 million of its loan into 207,215 common shares in March 2026.
- Accumulated deficit reached approximately $227.9 million as of March 31, 2026.
- Net cash used in operating activities was $(27.1) million in Q1 2026, compared to $(16.6) million in Q1 2025.